Definitive Contract 75N95022C00017
Award Date
7/14/22
Potential Completion Date
7/14/23
Potential Value
$250K
Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Not listed
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $15,375 firm-fixed-price purchase order contract awarded by the National Human Genome Research Institute, a civilian agency within the Department of Health and Human Services, to the New York Stem Cell Foundation, Inc., a non-profit organization. The contract is for services related to stem cell research, including generating induced pluripotent stem cell lines from patients with Alzheimer's disease and related dementias, differentiating stem cells into insulin-producing beta cells,...
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $150,000.00 firm fixed-price purchase order contract to the New York Stem Cell Foundation Inc., a non-profit organization that conducts stem cell research. The contract is for services related to stem cell research, including generating induced pluripotent stem cell lines, differentiating stem cells into insulin-producing beta cells, and expanding and validating neural...
This is a $241,500 firm fixed price contract awarded by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services, to the New York Stem Cell Foundation Inc., a non-profit organization. The contract is for the generation and characterization of human induced pluripotent stem cells (iPSCs), neural progenitor cells (NPCs), and stable transgenic iPSC lines from individuals with mood and anxiety disorders. This contract does not have a set-aside...
This $238,000.00 firm-fixed price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to the New York Stem Cell Foundation, Inc., a non-profit organization that conducts stem cell research. The contract is for the derivation of induced pluripotent stem cells, which aligns with the foundation's work in generating stem cell lines, differentiating them into various cell types, and...
This is a $1,405,000.00 firm fixed price purchase order contract awarded by the National Human Genome Research Institute, a component of the Department of Health and Human Services, to the New York Stem Cell Foundation Inc., a non-profit organization. The contract is for services related to beta cell differentiation and cell assays, which aligns with the original solicitation that sought the development of assays to evaluate the differentiation of stem cells into insulin-producing beta cells. No...
This is a $1,399,499.93 firm fixed-price definitive contract awarded by the National Eye Institute, a civilian agency within the Department of Health and Human Services, to the New York Stem Cell Foundation Inc., a non-profit organization. The purpose of this contract is to obtain induced pluripotent stem cells (iPSCs) to advance the study of the functional basis of genetic variants associated with age-related macular degeneration (AMD). No set-aside designation was used for this award. The...
This federal contract award from the National Human Genome Research Institute, an agency within the U.S. Department of Health and Human Services, was made to the New York Stem Cell Foundation Inc., a non-profit organization that conducts stem cell research. The contract, valued at $425,000.00, is for the generation of 50 induced pluripotent stem cell (iPSC) lines from fusion study fibroblast cell lines. No set-aside designation was used for this contract. The New York Stem Cell Foundation Inc....
The National Institute of Drug Abuse awarded a $414,000 firm fixed price definitive contract to New York Stem Cell Foundation Inc. to provide expansion, differentiation, and validation of 36 neural progenitor cell lines derived from induced pluripotent stem cells obtained from subjects with psychiatric conditions. The original solicitation sought proposals to outsource these services within specified timeframes, with an emphasis on technical approach. New York Stem Cell Foundation will...
The National Institute on Aging, a component of the National Institutes of Health within the Department of Health and Human Services, awarded a firm-fixed price purchase order valued at $3.4 million to New York Stem Cell Foundation Inc. The contract calls for the contractor to generate up to 200 induced pluripotent stem cell lines derived from fresh whole blood or peripheral blood mononuclear cells of patients with Alzheimer's disease or related dementias. The cell lines must be collected by...
This is a $122,400.00 firm fixed-price purchase order contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Applied Stemcell, Inc., a minority-owned, woman-owned small business. The contract is for molecular and pathophysiological studies of Parkinson's disease dementia and does not have a set-aside designation. Applied Stemcell, Inc. provides gene editing services and good manufacturing practice (GMP) induced...